The U.S. Food and Drug Administration granted Emergency Use Authorization to a combination of Eli Lilly’s and Incyte’s rheumatoid arthritis drug Olumiant (baricitinib) and Gilead Sciences’ remdesivir as a treatment for hospitalized patients diagnosed with Covid-19 who require supplemental oxygen or ventilation.
World’s top intensive care body advises against remdesivir for sickest Covid patients
Antivirals, Coronavirus Disease 2019 (COVID-19), Dexamethasone, Doctors, EU, Gilead, Hospitals, Interim Data, Medical Professionals, Papers, Remdesivir, Scientific Papers, Steroids, Therapeutics, World Health OrganizationThe antiviral remdesivir should not be used as a routine treatment for Covid-19 patients in critical care wards, the head of one of the world’s top bodies representing intensive care doctors said, in a blow to the drug developed by U.S. firm Gilead.
A World Health Organization-led scheme to supply Covid-19 drugs to poor countries is betting on experimental monoclonal antibody treatments and steroids but shunning Gilead’s remdesivir therapy, an internal document shows.
Gilead Sciences Inc. cut the company’s 2020 revenue forecast, citing lower-than-expected demand and difficulty in predicting sales of remdesivir, the only treatment approved in the United States for patients hospitalized with Covid-19.
Shares of Gilead Sciences Inc. rose after the company’s antiviral drug remdesivir became the first approved treatment for Covid-19 in the United States.
Shares of Gilead Sciences jumped in trading following full approval for Veklury (remdesivir) as a treatment for Covid-19.
A row broke out over a World Health Organization (WHO) clinical trial which concluded that Gilead’s anti-viral drug remdesivir has little or no impact on a patient’s chances of surviving Covid-19.
WHO study says remdesivir did not cut hospital stay or mortality in Covid-19 patients
Antivirals, Clinical Trials, Coronavirus Disease 2019 (COVID-19), Covid-19 Data, Hospitalized COVID-19 Patients, Hydroxychloroquine, Immunomodulator Drugs, Monoclonal Antibodies, Mortality, R&D, Remdesivir, World Health OrganizationGilead Sciences Inc.’s remdesivir had little or no effect on Covid-19 patients’ length of hospital stay or chances of survival, a clinical trial by the World Health Organization (WHO) found.
The European Union agreed to pay more than 1 billion euros ($1.2 billion) to Gilead for a six-month supply of the company’s antiviral drug remdesivir, shortly before the publication of final results for the largest trial of the Covid-19 medication.
In a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines, Covid-19 antibodies last at least three months and so do symptoms for many.